Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
/ 17 items
#GSK↓
European Drugmakers Surge: Pfizer's US Pricing Deal Offers a Tariff Blueprint
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
Pfizer Leads the Way on Drug Pricing and Domestic Investment
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
Massive New Tariffs: How Trump’s Latest Duties Hit Drugs, Trucks, and Furniture
President Trump is hitting imports with massive new tariffs starting October 1st, targeting branded drugs (100%), heavy trucks (25%), and furniture.
Beam Therapeutics' Edge Against Wave's Trial Data
Beam Therapeutics rallied after Wave Life Sciences' WVE-006 trial data for alpha-1 antitrypsin deficiency (AATD) fell below expectations.